Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Down 43.8% in March

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 39,600 shares, a drop of 43.8% from the February 28th total of 70,400 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 62,300 shares, the days-to-cover ratio is presently 0.6 days.

Senti Biosciences Stock Performance

NASDAQ SNTI traded up $0.10 during trading hours on Friday, reaching $3.43. 9,037 shares of the company’s stock were exchanged, compared to its average volume of 784,513. The company has a market capitalization of $16.57 million, a price-to-earnings ratio of -0.22 and a beta of 2.52. The company’s 50-day moving average is $3.88 and its two-hundred day moving average is $3.47. Senti Biosciences has a one year low of $1.52 and a one year high of $16.94.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.13) by $2.46. The company had revenue of $5.86 million for the quarter, compared to the consensus estimate of $2.80 million. Research analysts predict that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Senti Biosciences in a research note on Monday, December 2nd.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Senti Biosciences stock. Virtu Financial LLC purchased a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned approximately 0.28% of Senti Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 25.73% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.